In contrast, the management of MSS cancers still predominantly relies upon conventional chemotherapies, as the most frequently encountered mutations in MSS CRC affect yet non‐druggable tumor suppressor genes, such as APC and TP53. This evidence concerns the gene TP53 and colorectal carcinoma.